Supernus presented interim results from an open-label Phase IV trial with Qelbree in adult patients with ADHD and mood disorders. Interim data for the first 95 patients who completed the trial ...

Founded in 2005, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and commercializes treatments for central nervous system (CNS) disorders, focusing on epilepsy, ADHD, and Parkinson’s disease.

Also Read: ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug There was no treatment difference between SPN-820 and placebo in the change ...

Supernus reported 2024 revenues of approximately $660 million, demonstrating profitability. Calbri, a non-stimulant ADHD medication, showed strong sales of $241 million. The company plans to ...

About Supernus Pharmaceuticals ... includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based ...

Supernus presented interim results from an open label Phase IV trial with Qelbree in adult patients with ADHD and mood disorders. Interim data for the first 95 patients who completed the trial ...

In addition, earlier this month, at the Annual National Psychopharmacology Update Conference, Supernus presented interim results from an open-label Phase IV trial with Qelbree in adult patients with ...

Calvary, an ADHD medication, showed significant growth in prescriptions and sales. The company maintains a strong cash position with no debt. Supernus Pharmaceuticals demonstrated solid growth in ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

Labels, often described as limiting, may have positive outcomes on multiple dimensions when it comes to diagnosis and ...

ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for total ...